Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
39 hedge funds and large institutions have $84.6M invested in Inozyme Pharma in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 10 closing their positions.
0.11% less ownership
Funds ownership: 78.68% → 78.57% (-0.11%)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
17% less funds holding
Funds holding: 47 → 39 (-8)
43% less capital invested
Capital invested by funds: $149M → $84.6M (-$64.8M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
80% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$1.74M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$606K |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$181K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$166K |
| 5 |
Renaissance Technologies
New York
|
+$134K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$2.19M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$510K |
| 3 |
CA
CHI Advisors
New York
|
-$136K |
| 4 |
E
Ergoteles
New York
|
-$122K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$72.7K |
INZY Hedge Fund Activity: Q3 2022 in Review
39 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q3 2022, worth a combined $84.6M — down 43% from $149M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of INZY and 2 opened new positions — a net loss of 8 holders — while 14 trimmed existing stakes and 12 added.
The largest buyer was Janus Henderson Group, adding an estimated $1.74M. The largest seller was Deerfield Management, cutting an estimated $2.19M.
- 39 institutional investors held Inozyme Pharma (INZY) as of Q3 2022, down from 47 in Q2 2022.
- Funds reported $84.6M of Inozyme Pharma stock for Q3 2022, down 43% quarter-over-quarter.
- 2 funds opened new Inozyme Pharma positions in Q3 2022 and 10 closed out, a net change of -8 holders.
- The largest Inozyme Pharma buyer in Q3 2022 was Janus Henderson Group, an estimated $1.74M added.
- The largest Inozyme Pharma seller in Q3 2022 was Deerfield Management, an estimated $2.19M sold.
Based on aggregated 13F filings for Q3 2022.